Troglitazone (CS-045) ameliorates albuminuria in streptozotocin-induced diabetic rats.
We studied the effect of troglitazone, a new oral antidiabetic agent that potentiates insulin action and reduces insulin resistance, on albuminuria in streptozotocin (STZ)-treated diabetic rats. Without affecting blood glucose level, blood pressure, and creatinine clearance, troglitazone treatment of diabetic rats significantly decreased the diabetes-associated albuminuria at all time points studied 14 to 12 weeks of treatment: diabetic 510 +/- 161 micrograms/24 h v diabetic treated 112 +/- 34 micrograms/24 h at 12 weeks, P < .05). These data suggest that troglitazone has potential in the treatment of diabetic nephropathy.
Fujii
M
M
First Department of Internal Medicine, Kyoto Prefectural University of Medicine, Japan.
Takemura
R
R
Yamaguchi
M
M
Hasegawa
G
G
Shigeta
H
H
Nakano
K
K
Kondo
M
M
D000419:Albuminuria / Q000188:drug therapy* / Q000209:etiology* / Q000652:urine; D000818:Animals; D002839:Chromans / Q000627:therapeutic use*; D003921:Diabetes Mellitus, Experimental / Q000652:urine*; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D008297:Male; D051381:Rats; D017208:Rats, Wistar; D013844:Thiazoles / Q000627:therapeutic use*; D045162:Thiazolidinediones; D000077288:Troglitazone
D002839:Chromans; D007004:Hypoglycemic Agents; D013844:Thiazoles; D045162:Thiazolidinediones; D000077288:Troglitazone